| " In the light of recent evidence that some antihypertensive drugs with alpha-1 blocking properties reduce blood pressure (BP) and total cholesterol (chol), increasing chol content in the non-atherogenic high density lipoproteins (HDL-chol), the effects of urapidil, a peripheral alpha-1 adrenoceptor antagonist, with a central action component on BP and plasma lipids were evaluated in 49 mild, hypertensive patients with mild to moderately severe hypercholesterolemia (serum chol 220-320 mg/dl) for a 6 month period in a double-blind randomized study versus placebo." | 5.07 | Urapidil in hypercholesterolemic hypertensive patients. ( Ferrara, LA; Fogari, R; Leonetti, G; Mancini, M; Mazzola, C; Zanchetti, A, 1994) |